Cogent Biosciences, Inc.
Cogent Biosciences, Inc.
Explore linked clinical trials.7 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Mast Cell Activation Disorders, Mastocytosis, Systemic, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Soft Tissue Neoplasms, acute myeloid leukemia, bone marrow disorder, chronic myelomonocytic leukemia, connective tissue disorder, connective tissue neoplasm, cutaneous mastocytosis, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, leukemia, maculopapular cutaneous mastocytosis, mast cell leukemia, mastocytosis, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm, skin disorder, skin neoplasm, skin pigmentation disorder, type III hypersensitivity disease | Recruiting | Phase 2 | 2026-09-15 | NCT04996875 | |
| A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 | 2026-09-04 | NCT07361562 | |
| A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, breast disorder, breast neoplasm, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, skin disorder, uterine disorder | Recruiting | Phase 1 | 2026-08-26 | NCT07383506 | |
| (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors | Digestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, connective tissue neoplasm, digestive system disorder, digestive system neoplasm, gastrointestinal stromal tumor, metastatic malignant neoplasm, neoplasm | Recruiting | Phase 3 | 2026-06-16 | NCT05208047 | |
| (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis | Hemic and Lymphatic Diseases, Mast Cell Activation Disorders, Mastocytosis, Systemic, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, hematologic disorder, immune system disorder, indolent systemic mastocytosis, mastocytosis, neoplasm, superficial spreading melanoma, type III hypersensitivity disease | Active, not recruiting | Phase 2 | 2026-05-22 | NCT05186753 | |
| A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors | Cirrhosis, Familial, with Pulmonary Hypertension, Neoplasms by Histologic Type, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-04-17 | NCT06777316 | |
| SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, digestive system disorder, digestive system neoplasm, gastrointestinal stromal tumor, neoplasm, sarcoma | Active, not recruiting | Phase 2 | 2025-10-31 | NCT06208748 |